This trial will assess effects of enrollment in a comprehensive telehealth platform, RecoveryPad (RP), in adults with moderate or severe opioid use disorder.

Inclusion Criteria:

• Can speak, read and write in English
• Provision of signed and dated informed consent form
• Screened positive for OUD, moderate or severe, based on the Diagnostic and Statistical Manual-5th Edition
• Have a working cell phone number and working device that can access a web browser and receive texts (i.e., smartphone, tablet or computer)
• Can provide a working email address OR be willing to create one

Exclusion Criteria:

• Current use of buprenorphine, methadone, or naltrexone for a substance use disorder
• Pregnancy
• Known current suicide risk based on participant self-report
• On parole or incarcerated at time of enrollment based on participant self-report

In accordance with the HEAL Public Access and Data Sharing policy, de-identified IPD underlying the results reported in study-related publications will be shared. These will include participant-level data such as demographics/baseline characteristics, randomization results, and primary and secondary outcome measures.Direct identifiers will not be shared. Data will be de-identified using accepted standards.

The de-identified IPD and relevant supporting documentation will be available no later than 12 months after completion of primary analyses and publication of the primary results, or within the period required by the HEAL Initiative data sharing policy. Data will remain available for a minimum of 3 years after the initial release date, subject to repository support and other policy requirements.

All shared data and associated supporting documentation will be uploaded to the National Addiction and Health Data Archive Program.